-- Anand Reddi appointed vice president, patient advocacy, access, and digital innovation -- -- Bill Tan, PharmD, appointed vice president, clinical operations program lead -- REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies,...

REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced a grant of stock options to a new employee. On March...

Responds to Intent to Nominate Directors from Sonic Fund Sonic’s Attempt to Control the Board Not in the Best Interests of Adverum or the Company’s Stockholders REDWOOD CITY, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...

-- BLA submission targeted in 2024 -- -- Alignment on clinical development and CMC requirements from recent interactions with FDA -- -- Two global Phase 3 trials expected to enroll 900 patients in total; Targeted to initiate in 4Q 2021 -- -- Company to host conference...

Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc....

REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Reed V. Tuckson, M.D., FACP as an...

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Christopher J. DeRespino as chief...

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of data from Cohorts 1-4 of the...

-- Long-term safety and sustained anti-VEGF protein expression out to 30 months following a single IVT injection of ADVM-022 in NHPs --REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy...

-- INFINITY Phase 2 trial fully enrolled; data expected in 2H21 -- -- First pivotal trial planned for ADVM-022 in wet AMD in mid-2021; regulatory agency discussion planned 1Q21 -- -- New commercial GMP manufacturing facility expected to be production-ready by YE23 --...